With a US complete response letter for urea cycle disorder therapy ACER-001, rare disease specialty company Acer Therapeutics Inc. holds CRLs for both of the 505(b)(2) new drug applications it has filed – a reminder of the regulatory challenges that can remain for “de-risked” drug candidates with clinical experience in other fields and formulations.
Acer Therapeutics is focused on finding “drugs that were misunderstood” in their original development programs but could have a new life treating serious orphan diseases, CEO Chris Schelling explained in...
Insights And Ideas From Acer’s Experience
- Manufacturing issues often trip up applications using the 505(b)(2) route.
- Acer’s first NDA for Edsivo used data from a trial already conducted by a Paris-based university hospital,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?